When Indian Pharma Builds in America: Insuring a US Plant Ahead of the 2028 Generic Tariff

The trade measure that Indian formulators are now planning around has a published timetable. As reported by ThePrint in 2026, imported generic medicines face a 0 per cent tariff for two years from 1 August 2026, then 100 per cent from 2028 and 200 per cent thereafter, implemented using Section 232 of the Trade Expansion Act of 1962. Patented and branded medicines stay on the existing framework, so the burden falls squarely on the segment where Indian companies hold the largest US share.

The arithmetic is what makes this a board matter rather than a trade-desk matter. The Hans India reported in 2026 that Indian generics typically run 8 to 12 per cent EBITDA margins, which means a 100 per cent tariff would effectively wipe out margins on US-bound shipments. There is no pricing route out of that for a commoditised oral solid dosage line competing against other suppliers in the same tariff bracket.

As India Briefing described the policy in 2026, the design intent is to push companies to establish pharmaceutical manufacturing plants inside the United States rather than depend on imported generics. That is the point at which the question stops being about customs classification and becomes an insurance question, because a US manufacturing site is a materially different risk object from an Indian site that exports to the US.

Indian pharma groups that export to the US have generally carried a single Indian-issued products liability tower, sometimes with a worldwide including USA/Canada extension, and that structure has worked because the insured entity, the manufacturing risk, and the employees were all in India. A US plant changes every one of those facts.

Insurance in the United States is regulated at state level. Each state licenses its own admitted insurers, approves their forms and rates, and maintains a separate surplus lines route for risks the admitted market declines. The surplus lines route is conditional: in most states the broker must document a diligent search of the admitted market before placing with a non-admitted carrier, and surplus lines premium tax is payable to the home state of the insured. Writing a US-situated risk directly off an Indian policy satisfies neither route.

The practical consequences of getting this wrong are the ones a CFO should care about:

• Enforceability. A policy issued by a carrier with no US licence and no surplus lines eligibility is difficult to enforce in a US court, which is exactly where a US products or premises claim will be litigated.
• Tax. Unpaid surplus lines and federal excise taxes on offshore premium accrue with penalties, and they surface during diligence long after the placement.
• Certificates. US landlords, construction lenders, distributors, group purchasing organisations, and state licensing bodies all require certificates of insurance naming a carrier they recognise. An Indian certificate of insurance will not clear a US distributor's vendor onboarding.
• Contractual defaults. Supply agreements and leases specify minimum limits and carrier ratings. Non-conforming cover is a breach whether or not a claim ever occurs.

The general principles are covered in more depth in our post on admitted versus non-admitted insurance for Indian multinationals. For a US site the answer is settled: the local operating entity buys admitted US paper, and the Indian master programme sits above it.

Indian boards consistently underestimate this line because the Indian analogue, cover written under the Employee's Compensation Act, 1923 alongside ESIC, is a small premium item on a large factory schedule. US workers compensation is a different order of expense and a different order of compliance risk.

Three features drive the difference. First, benefits are set by state statute, not by policy limit, so the workers compensation part of the policy responds to whatever the state schedule provides for medical treatment, indemnity for lost wages, and permanent disability. Medical benefits in most states are unlimited in amount and duration for a compensable injury. Second, coverage is compulsory for employers in effectively every state, with penalties for operating uninsured that can include stop-work orders and personal liability for owners and officers. Third, a handful of states operate monopolistic funds where cover must be purchased from the state itself rather than a commercial carrier, which means the local policy in those states cannot be integrated with a commercial programme in the usual way.

The employers liability section, which responds to injury suits falling outside the compensation bargain, is where the master programme has a role. Employers liability limits sit under the umbrella tower, and the umbrella has to be written to sit over the specific US employers liability policy, not over an Indian workers compensation wording.

Payroll classification codes drive both the premium and the year-end audit. A plant that classifies packaging, quality control, maintenance, and warehouse staff into the wrong codes will pass underwriting and then face a premium audit adjustment after the first policy year. Budget the classification exercise into the pre-hire plan rather than treating it as a broker formality.

An Indian formulator already carries products liability for US-bound shipments, so the instinct is to treat the US plant as an extension of the same exposure. Two things change.

The first is jurisdiction of manufacture. A defect claim arising from a batch made in New Jersey is a domestic US product claim, with the manufacturing entity, the quality records, the batch documentation, and the deposition witnesses all inside the United States. Discovery reaches the site, its deviation reports, and its CAPA files. The evidentiary exposure is far wider than for an imported product where the plaintiff's route to Indian manufacturing records runs through slower channels.

The second is the defence-cost structure. US general liability and products policies commonly provide defence in addition to the limit of indemnity, which is favourable, but that structure disappears as you move up a tower into excess and surplus lines layers, where defence within limits is common. A mixed tower with defence outside the limit at the primary and inside the limit above it produces exactly the erosion pattern that surprises Indian risk managers, a point we cover in how defence costs interact with liability limits.

The programme features that matter for a generic manufacturer are specific:

1. Batch recall and product withdrawal cover with a limit sized against the cost of retrieving distributed inventory through US wholesalers and pharmacy chains, which is the dominant cost in most recalls.
2. Failure-to-supply and contractual penalty exposure under US supply agreements, which is generally excluded from a standard products policy and needs to be underwritten separately or accepted as retained risk.
3. Clear allocation between the Indian entity and the US entity where an API is made in India and the finished dosage form is made in the US, so that neither insurer can point to the other on a defect of unclear origin.
4. Named insured and additional insured schedules that pick up the US entity, its contract manufacturers, and its distributors in the form the supply agreements demand.

Our earlier post on global product liability coverage for Indian pharma sets out the base position that a US plant builds on.

The exposure that surprises first-time US employers is not injury. It is employment litigation. A US plant hires a workforce of several hundred people across shift patterns, with supervisors trained in Indian management norms, under a federal and state employment law regime that permits jury trials, punitive damages in some claim types, and plaintiff attorney fee recovery.

The claim types cluster predictably at a new manufacturing site: discrimination and harassment claims, wage and hour disputes over shift differentials, meal and rest breaks and overtime classification, retaliation claims following an internal complaint or a safety report, and wrongful termination claims during the ramp-down that follows an over-optimistic hiring plan.

Employment practices liability insurance responds to most of these, with two structural caveats that matter for a controlled programme. Wage and hour claims are usually excluded or sub-limited to a defence-costs-only allowance, which means the largest class exposure at a plant is the least covered. And the policy is claims-made, so retroactive dates, prior-knowledge conditions and the run-off provision on any future divestment need to be set deliberately at inception rather than at the first renewal.

The governance point is that the Indian parent's HR policies do not travel. Handbooks, complaint channels, investigation protocols, and manager training all have to be built to US standards before the first hire, because underwriters price EPLI on exactly those controls and claims turn on whether they existed and were followed. The mechanics of defending these claims are set out in our post on employment practices liability claims and defence.

The structure that works for a US site is a controlled master programme: locally admitted policies issued in the US by a licensed carrier for the compulsory and locally required lines, with an India-issued or GIFT City master policy providing difference in conditions and difference in limits above them.

What goes local, without exception, is workers compensation and employers liability, automobile liability for owned and hired vehicles, and general liability where a lease, lender, or supply agreement requires a locally recognised certificate. Property and business interruption on the US site are also normally placed on admitted paper because the mortgagee will insist on it.

What the master programme adds sits in three places. It provides difference in limits where the local general liability tower is placed at a limit below the group standard. It provides difference in conditions where the US wording is narrower than the group standard, for example on contingent business interruption from an Indian API supplier. And it consolidates the group retention so that a US loss and an Indian loss draw on the same aggregate rather than two separately negotiated deductible structures. The general design is set out in our post on controlled master programmes for Indian multinationals.

Three drafting details decide whether the structure works at claim time. The DIC/DIL trigger has to state whether it operates automatically on exhaustion of the local limit or requires a separate claim on the master. The currency of the master limit and the local limit have to be reconciled so that a rupee-denominated master limit and a dollar-denominated local limit do not produce an arithmetic dispute about exhaustion. And the policy wording has to address claims cooperation, because a US carrier defending a products suit will control the defence and the master insurer needs a contractual right to information without disturbing that control.

Financial interest cover is worth mentioning only to dismiss it as a substitute here. It protects the Indian parent's balance-sheet interest in the subsidiary, and it does nothing for a US injured worker, a US plaintiff, or a US lender who needs a certificate.

The insurance workstream for a US plant runs on the construction timeline, not after it. A workable sequence for a project targeting production before the 2028 tariff step is as follows.

1. At site selection, confirm the state's workers compensation regime, including whether it is a monopolistic-fund state, and price the payroll at the applicable classification codes. This is a site-selection input, not a post-decision cost.
2. At entity formation, fix the named insured structure across the US operating entity, the Indian parent, and any US holding company, and decide which entity is the first named insured on each local policy.
3. At groundbreaking, place US construction cover with the contractor's obligations and the owner's protective interest set out in the construction contract, and confirm the contractor's workers compensation and general liability meet the specified limits.
4. Before the first hire, put EPLI in force with a retroactive date at the date of first employment, and have the US employee handbook, complaint channel, and manager training in place because underwriters will ask for them.
5. Before the first commercial batch, restructure the products liability tower so that the US-manufactured product is insured on admitted US primary paper with the excess layers reconciled for defence-cost treatment, and reallocate the Indian tower to reflect the reduced export volume.
6. At the first renewal after commissioning, run a full programme reconciliation across the local and master policies to confirm no line is doubly insured and no line has fallen between them.

The tariff timetable gives Indian formulators a defined runway. The insurance decisions on that runway are ordinary, well-understood decisions, and they are only expensive when they are taken late.